

1 **Bridging the Sequencing Gap: N501Y SNP RT-qPCR Assay Detects First SARS-CoV-2 Beta**
2 **Variant in the Philippines**

3 Samantha Louise P. Bado¹, Niquitta B. Galap¹, Joanna Ina G. Manalo¹, Othoniel Jan T. Onza¹, Mary
4 Rose B. Pelingon¹, Joy Mariette L. Parayray¹, Justine Mae Palciso¹, Karen Iana C. Tomas¹, Miguel
5 Francisco B. Abulencia¹, Francisco Gerardo M. Polotan¹, Lei Lanna M. Dancel¹, Amalea Dulcene
6 Nicolasora^{1*}

7 ¹Advanced Molecular Technologies Laboratory, Research Institute for Tropical Medicine, Philippines

8 *corresponding author

9 Email: amaleanicolasora@gmail.com

10 **ABSTRACT**

11 Whole genome sequencing (WGS) is used extensively in identifying SARS-CoV-2 variants. However,
12 this method requires stringent sample acceptance criteria, long turn-around time (TAT), expensive
13 processing and maintenance costs, and highly skilled staff. Although sequencing offers comprehensive
14 pathogen insights, a cost-effective tool with faster TAT is beneficial in detecting SARS-CoV-2 variants
15 of concern (VOCs). Here, we used a single nucleotide polymorphism (SNP) RT-qPCR assay to detect
16 the N501Y mutation in banked SARS-CoV-2 RNA extracts (N=452) collected from December 2020 to
17 April 2021. Of the SARS-CoV-2 positives (n=367), 22% carried the N501Y mutation and were
18 classified as probable VOCs. This includes a sample that was confirmed to belong to the Beta lineage
19 and was collected earlier than the first reported Beta variant in the country suggesting an earlier
20 emergence of the variant. Validation experiments for the SNP RT-qPCR assay showed a limit of
21 detection (LOD) of 3.01 copies/μL for both N501 and 501Y targets. A 99.35% concordance with partial
22 S gene Sanger sequencing was observed confirming the presence of the N501Y SNP in 83 samples. In
23 conclusion, the optimized SNP RT-qPCR assay serves as an important complementary or alternative
24 tool for detecting probable SARS-CoV-2 variants, ensuring that samples ineligible for WGS are not
25 overlooked. This effectively resolves sequencing gaps, including stringent sample acceptance criteria,
26 extended TAT, and rigorous data analysis. Therefore, embracing this technology provides a rapid,
27 economical, and dependable solution for managing pathogens of public health concern.

28 Keywords: SARS-CoV-2, SNP RT-qPCR, N501Y mutation, Philippines

29 **INTRODUCTION**

30 The global emergence of SARS-CoV-2 variants of concern (VOCs) heightened the need for genomic
31 surveillance systems to maintain effective public health interventions during the COVID-19
32 pandemic(1). In late 2020, an emergence of mutations enhancing viral pathogenicity, transmissibility,
33 and antigenicity were observed(2). Three independent SARS-CoV-2 lineages, B.1.1.7/Alpha(3),
34 B.1.351/Beta(4), and P.1/Gamma(5), were introduced and rapidly multiplied in the population. While

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

35 these variants are characterized by a myriad of mutations across their genomes, they share the key spike
36 gene mutation N501Y(6). The mutation was identified as a possible determinant of enhanced infection,
37 providing the virus with a more efficient viral entry and the ability to evade anti-spike protein
38 antibodies(6–10).

39 The World Health Organization (WHO) recommended whole genome sequencing (WGS) for detecting
40 and identifying emerging SARS-CoV-2 variants(11). However, using such technology proves to be
41 challenging in resource-limited countries such as the Philippines due to its expensive processing and
42 maintenance costs. Additionally, the long turnaround time, stringent sample acceptability criteria, and
43 high technical requirements make it disadvantageous, especially in outbreak scenarios. Thus, alternative
44 methods with rapid and efficient workflows are needed to allow SARS-CoV-2 variant screening(12).

45 An RT-qPCR assay that targets variant-specific SNP mutations like N501Y can be used as a screening
46 tool for early variant classification(11). Laboratory-developed SNP RT-qPCR assays were implemented
47 in the surveillance measures in several countries, which allowed them to screen and identify probable
48 variants rapidly(13–17). In this paper, we optimized and used a SNP RT-qPCR assay to screen for the
49 variant-associated N501Y amino acid substitution in banked SARS-CoV-2 samples. We also describe
50 how it helped identify a missed Beta variant case in the Philippines.

51 **MATERIALS AND METHODS**

52 **Ethical statement**

53 All samples, protocols, and procedures described in this study are approved by the Research Institute
54 for Tropical Medicine Institutional Review Board (RITM-IRB) with IRB Number 2022-43. The written
55 informed consent requirement was waived based on the context of the emerging outbreak response.

56 **Clinical specimens**

57 RNA extracts from December 2020 to April 2021 collected from the National Capital Region (NCR)
58 and Region IV-A in the Philippines were acquired from the RITM Advanced Molecular Technologies
59 Laboratory (RITM-AMTL) COVID-19 specimen bank. Four hundred fifty-two (452) archived RNA
60 extracts of PCR-confirmed SARS-CoV-2 negative ($n = 85$) and positive ($n = 367$) samples were
61 retrieved and tested at the RITM-AMTL. All patient samples were de-identified and anonymized in all
62 materials and documents used in this study.

63 **cDNA synthesis**

64 Complementary DNA (cDNA) was synthesized from RNA extracts using Moloney Murine Leukemia
65 Virus (M-MLV) Reverse Transcriptase with RNaseOUT™ Recombinant Ribonuclease Inhibitor and
66 Random Primers according to the manufacturer’s protocol (Invitrogen, CA, USA).

67 **N501Y SNP RT-qPCR assay**

68 The synthesized cDNA was subsequently tested using the N501Y SNP RT-qPCR assay that targets the
69 N501Y wild type and mutant alleles. All primers and probes (Table 1) were adapted from the National
70 Institute of Infectious Diseases (NIID) of Japan(18). The SNP RT-qPCR mastermix has a total volume
71 of 10µL containing 5µL 2X Taqman Fast Advanced Master Mix (Applied Biosystems, CA, USA),
72 3.2µL UltraPure™ Distilled Water (Invitrogen, CA, USA), 0.6µM primers, 0.1µM probes, and 1µL
73 cDNA template. The amplification of the N501 and 501Y targets was detected through the FAM and
74 VIC channels, respectively. The thermocycling profile optimized was 60°C for 1 minute, 50°C for 2
75 minutes, 95°C for 2 minutes, and 40 cycles of 95°C for 3 seconds and 60°C for 30 seconds, then a cycle
76 of 60°C for 1 minute, using the 7500 Fast Real-Time PCR System (Applied Biosystems, CA, USA).
77 Laboratory-confirmed SARS-CoV-2 negatives served as the negative control, and *in vitro* transcribed
78 N501 and 501Y oligonucleotides served as positive controls for each RT-qPCR run.

79 Table 1. List of primers, probes, and positive control sequences used for N501Y mutation detection.

Use	Name	Sequence (5' to 3')
	Forward Primer	CTTGTAATGGTGTTRAAGGTTTTAATTGT
	Reverse Primer	GGTGCATGTAGAAGTTCAAAAGAAAG
	N501 (wild type) Probe	FAM-CCAACACCATTAGTGGGTTG-MGB
	501Y (mutant) Probe	VIC-CCAACACCATAAGTGGGTTG-MGB
N501Y SNP RT-qPCR	N501 Control	CTTGTAATGGTGTGAAGGTTTTAATTGTTACTTTCCTTTACA ATCATATGGTTTCCAACCCACTAATGGTGTGGTTACCAACC ATACAGAGTAGTAGTACTTTCTTTTGAAGTTCTACATGCACC
	501Y control	CTTGTAATGGTGTGAAGGTTTTAATTGTTACTTTCCTTTACA ATCATATGGTTTCCAACCCACTTATGGTGTGGTTACCAACC ATACAGAGTAGTAGTACTTTCTTTTGAAGTTCTACATGCACC
Partial Spike gene Sanger sequencing	F46 Forward Primer	CCTTCACTGTAGAAAAAGGAATC
	R46 Reverse Primer	TGGAAACCATATGATTGTAAAGGA
	F47 Forward Primer	TATCAGGCCGGTAGCACAC
	R47 Reverse Primer	CATATGAGTTGTTGACATGTTTCAG

80 **N501Y SNP Assay Validation**

81 The SNP assay's limit of detection (LOD) was validated for both N501 and 501Y targets using *in vitro*
82 transcribed N501 and 501Y oligonucleotides. Starting with 3.01×10^9 copies/ μ L, 10-fold serial dilutions
83 were performed down to 3.01×10^{-2} copies/ μ L. All dilutions were tested in triplicates. The last two
84 dilutions with a 100% detection rate for each target were tested in 20 replicates. The lowest dilution
85 with at least a 95% detection rate is considered the LOD.

86 A panel of four hundred fifty-two (452) samples that were previously tested for the presence of SARS-
87 CoV-2 using a commercial kit (Sansure Biotech) were used in this study. The SARS-CoV-2-positives
88 were classified according to the Ct values of their ORF1ab gene target during the initial screening test:
89 Low Ct is less than 25, Mid Ct is between 25 and 30, and High Ct is greater than 30. The samples were
90 tested using the N501Y SNP RT-PCR assay to confirm the assay's viability in detecting SARS-CoV-2
91 and distinguishing between N501Y wild type and mutant relative to Ct values.

92 **PCR amplification and Partial Spike Gene Sanger Sequencing**

93 To evaluate the accuracy of the SNP RT-qPCR assay in detecting the N501Y SNP, a subset of 308
94 SARS-CoV-2-positive samples were sequenced using the Sanger sequencing method. This method is
95 the gold standard for identifying SNPs and basecalling accuracy. Primers adapted from the National
96 Reference Center for Emerging Viral Infections(19) flanking the Spike gene region were used to
97 amplify two overlapping fragments covering positions 914-1981 of the Spike gene.

98 The conventional PCR reactions were carried out using the Ex Taq® PCR kit (TaKaRa, Kusatsu,
99 Japan). The first round PCR mastermix has a total volume of 20 μ L containing the F46 and R47 primers
100 at 500nM each, 2.0 μ L of 10x Ex Taq buffer, 1.6 μ L of 10 μ M dNTP mix, 0.1 μ L of Taq enzyme, and
101 0.1 μ L cDNA. Pre-denaturation was set at 94°C for 2 minutes, followed by 35 cycles of denaturation at
102 94°C for 30 seconds, annealing at 55°C for 30 seconds, and extension at 72°C for 1 minute, then
103 followed by a final extension at 72°C for 10 minutes. Two separate hemi-nested PCR runs were
104 performed, one using F46 and R46 primers and the other using F47 and R47 primers (see Table 1).
105 Each reaction mix consists of 500nM each of the primers, 2.0 μ L of 10x Ex Taq buffer, 1.6 μ L of 10 μ M
106 dNTP mix, 0.1 μ L of Taq enzyme, and 0.5 μ L of template with a total volume of 20 μ L. The PCR profile
107 from the first round was altered for the nested round by reducing the extension stage from 1 minute to
108 30 seconds at 72°C. The PCR products were visualized using agarose gel electrophoresis. Samples with
109 clear, distinct bands were purified using PureLink PCR purification kit (Invitrogen, CA, USA)
110 following the manufacturer's protocol. Samples were sent to a third-party sequencing facility for
111 sequencing using the ABI 3730XL system.

112 **Sequence analysis**

113 Partial S gene sequences were trimmed and assembled using MEGA X and Aliview software(20,21),
114 and alignment was done using the S gene reference sequence (EPI_ISL_402124). Consensus FASTA
115 sequences were uploaded to the Stanford Coronavirus Antiviral & Resistance Database (CoVDB) to
116 check for the presence of the N501Y mutation. The program uses the reference sequence Wuhan-Hu-1
117 (NC_045512.2) for alignment(22).


118 **Phylogenetic Analysis**

119 The N501Y-containing sample with the earliest collection date, PH-RITM-0142, was sequenced
120 through a modified ARTIC protocol(23). Fifty-seven (57) of its closely related sequences from the
121 Philippines (EPI_SET_230914kr) were obtained using *AudacityInstant* (V5.1.0) on GISAID(24) on
122 September 12, 2023. The sequences were aligned using MAFFT v7.520(25) and a phylogenetic tree
123 was generated using IQ-TREE v2.2.3(26) with a GTR nucleotide substitution model and a fixed clock
124 rate. The resulting tree was input into TreeTime v0.10.1(27) with 1000 iterations for bootstrapping to
125 generate a time-scaled phylogeny.

126 **RESULTS**

127 **N501Y SNP RT-qPCR Assay Validation**

128 The SNP RT-qPCR assay's limit of detection (LOD) was validated to be 3.01 copies/ μ L for both N501
129 and 501Y targets with 100% and 95% detection rates in 20 replicates, respectively (see Table S1). All
130 SARS-CoV-2 negative samples (n=85) also showed negative results using the SNP assay. Among the
131 SARS-CoV-2-positives, 48 (13%) showed negative results and were not classified by the SNP RT-
132 qPCR assay as either wild type or mutant as shown in Figure 1. Of these 48 samples, one had a mid-
133 range Ct value and 47 exhibited a high Ct value for the SARS-CoV-2 PCR screening test. Figure 1
134 illustrates a decreasing trend in the detection rate of the SNP RT-qPCR assay as the Ct value of the
135 samples increases. The concordance rate between the commercial kit (Sansure Biotech) and the SNP
136 RT-qPCR assay is 100% and 87% in SARS-CoV-2 negative and positive samples.



137

138 Figure 1. SARS-CoV-2 detection rate of N501Y SNP RT-qPCR assay based on Ct value
 139 generated from the ORF1ab gene target of the Sansure RT-qPCR run. The samples were
 140 classified based on the following scheme: Low Ct <25, Mid Ct 25-30, and High Ct >30.

141 Concordance testing with partial S gene Sanger sequencing using 308 SARS-CoV-2-positive samples
 142 (225 wild types and 83 with N501Y mutation) shows an overall percent agreement (OPA) of 99.35%
 143 where the SNP RT-qPCR assay correctly classified 306 samples. Only two samples containing the 501Y
 144 mutation according to Sanger sequencing exhibited discordant results (see Table 2).

145 Table 2. Concordance testing results between N501Y SNP RT-qPCR assay and partial S gene Sanger
 146 sequencing.

SNP detection	Sanger mutant (501Y)	Sanger wild type (N501)	Total
SNP detected (501Y)	81	0	81
SNP not detected (N501)	2	225	227
Total	83	225	308


147

148 Comparing the SARS-CoV-2 lineage frequency distribution using SNP RT-qPCR vs Whole 149 Genome Sequencing

150 Of the 452 samples subjected to N501Y SNP RT-qPCR, a shift in the proportion of samples without
 151 the N501Y mutation (N501) to those with the N501Y mutation (501Y) was observed between


152 December 2020 and April 2021 (Figure 2A). The detection rate of N501Y mutants increased by 95.32%
153 from December 2020 to April 2021. The increasing trend coincides with that of Philippine whole
154 genome sequences as shown in Figure 2B. However, it can be noted that the detection of the spike
155 mutation is earlier for the SNP RT-qPCR (December 2020) as compared to WGS (January 2021).
156 Notably, one of the samples that carried the N501Y mutation, PH-RITM-0142, was later confirmed by
157 WGS to be a Beta variant. The sample was collected on December 9, 2020, which is earlier than the
158 first reported Beta case in the country.

159 The prevalence of the N501Y mutation among tested samples aligns with the increase in confirmed
160 cases of SARS-CoV-2 and the shift from the predominantly circulating lineage B.1.1.63 to the Alpha
161 and Beta variants (Figure 3). However, sequencing data suggests that the first Beta variant cases were
162 only introduced in the country around February 2021, which contrasts with our identification of a Beta
163 variant sampled in December 2020.



164

165 Figure 2. (A) Detection rate of N501 and 501Y among SARS-CoV-2 positive samples from
166 December 2020 to April 2021 using SNP RT-qPCR, (B) Philippine whole genome
167 sequences collected between December 2020 and April 2021 carrying the spike mutation.




168

169 Figure 3. Number of sequenced genomes for each major variant (bars) and confirmed
 170 COVID-19 cases (black solid line). D614G corresponds to non-major variants carrying the
 171 D614G mutation.

172 **Phylogenetic Analysis**

173 Fifty-seven (57) B.1.351/Beta sequences collected in the Philippines that were closely related to PH-
 174 RITM-0142 were generated using *AudacityInstant* (V5.1.0) on GISAID. In Figure 4, phylogenetic
 175 analysis revealed that the PH-RITM-0142 B.1.351/Beta variant was introduced earlier than what was
 176 reported to be the first case.



177

178 Figure 4. Phylogenetic analysis of the first N501Y case - PH-RITM-0142 - and its closest
 179 sequences collected in the Philippines.

180 DISCUSSION

181 This study documents how we developed, optimized, and validated a SNP RT-qPCR assay to detect the
182 N501Y mutation in archived SARS-CoV-2 samples collected from NCR and Region IV-A in the
183 Philippines from December 2020 to April 2021. Our findings demonstrate its potential use in public
184 health emergency response. N501Y is a key spike gene mutation shared by the Alpha, Beta, and Gamma
185 variants(28), which were VOCs circulating globally at the time of collection of the archived samples.
186 The first reported VOC case in the Philippines belonged to the Alpha lineage and was reported on
187 January 13, 2021(29,30), although current data from GISAID shows that the Alpha variant was present
188 as early as December 10, 2020 (EPI_ISL_1081795; <https://doi.org/10.55876/gis8.240515yr>). Data also
189 shows that the first Beta case detected in the country was on January 31, 2021 (EPI_ISL_4743768;
190 <https://doi.org/10.55876/gis8.240515ay>). Interestingly, in testing the archived samples, we detected the
191 N501Y mutation from a sample collected on December 9, 2020, later confirmed by WGS to be of
192 B.1.351/Beta lineage. The sample initially did not meet the stringent criteria for WGS since its ORF1ab
193 Ct value is 32.63, which is beyond the recommended Ct value of ≤ 30 (31). This case highlights a gap in
194 variant surveillance efforts, where samples with Ct values exceeding the eligibility criteria for WGS
195 might be excluded from sequencing, potentially leading to the missed detection of important variants.
196 In acknowledgment of such instances, non-sequencing methods like our optimized PCR-based SNP
197 (N501Y) detection assay become a crucial source of information for rapid variant detection.

198 Our optimized SNP RT-qPCR assay demonstrates high concordance with partial S gene Sanger
199 sequencing in detecting the N501Y SNP mutation. These findings signify the potential impact of
200 utilizing rapid detection methods, in complementary with sequencing methodologies, in the quick
201 estimation of the prevalence of probable variants in the community to help facilitate immediate
202 preventive measures against its spread.

203 Analytical performance validation of our SNP RT-qPCR assay showed an LOD of 3.01 copies/ μ L for
204 both targets in the validation experiments. When compared with a commercial SARS-CoV-2 diagnostic
205 kit that targets the N and ORF1ab SARS-CoV-2 genes in a panel of clinical respiratory samples with
206 low- intermediate- and high-concentration of SARS-CoV-2 genetic material, our in-house SNP
207 (N501Y) assay could only detect SARS-CoV-2 from 46% of samples with Ct values >30 (estimated to
208 have low SARS-CoV-2 genetic material concentration) and subsequently classify them as either wild
209 type or mutant for the N501Y mutation. While this indicates that our SNP assay has a lower analytical
210 sensitivity than the comparator commercial SARS-CoV-2 diagnostic kit whose LOD is 0.2
211 copies/ μ L(32), we emphasize that the assay is not meant to be used as a standalone diagnostic test for
212 SARS-CoV-2. Its primary utility is for detecting the target SNP, in this case, the N501Y mutation.

213

214 In terms of detecting the N501Y SNP, the assay exhibited high diagnostic specificity and sensitivity
215 with an overall percent agreement (OPA) of 99.35% relative to Sanger sequencing. These results show
216 that the assay is sufficiently specific and sensitive in detecting the N501Y mutation. This makes it a
217 useful tool for screening for probable variants, followed by sequencing as a confirmatory step.

218

219 Our retrospective testing revealed that B.1.351/Beta was detected in a sample (PH-RITM-0142)
220 collected on December 9, 2020, from a high-risk patient with no known exposure and travel history.
221 This finding suggests earlier circulation of the Beta variant compared to the officially reported date of
222 March 2, 2021, which was based on the earliest confirmed case at that time, whose sample was collected
223 in late January(33). This also shows that SARS-CoV-2 VOCs were already circulating in the country
224 before its first public report in January 2021. Initially, the sample was not included in the subset that
225 was routinely sequenced for surveillance since its RT-qPCR results showed a high Ct value (32.63)
226 indicating weak positivity. However, since the SNP RT-qPCR results showed that it carried the N501Y
227 mutation, we subjected it to WGS using Oxford Nanopore Technology (ONT) for confirmation. Results
228 showed that the sample belonged to the B.1.351/Beta lineage with 81% genome coverage. Moreover,
229 our phylogenetic analysis in Figure 4 further supports the claim that PH-RITM-0142 predates the Beta
230 transmission window in the Philippines, which occurred from January to August 2021 with the first
231 officially reported first case on January 31, 2021. Additionally, it is not linked to the subsequent increase
232 in B.1.351/Beta cases. These results are crucial for determining when and how the B.1.351/Beta variant
233 entered and spread in the Philippines. It suggests that there was an introduction of Beta earlier than
234 initially thought.

235

236 While genomic sequencing is important for surveillance, it is still limited to specialized and highly
237 equipped laboratories. It also requires high quality and concentration of SARS-CoV-2 viral RNA as a
238 quality control checkpoint. In the context of outbreak response, a PCR-based method that can screen
239 for probable variants and be deployed more easily might have a greater impact on disease control
240 measures. A multi-step screening concept was developed across diagnostic and research laboratories in
241 Switzerland to understand the spread of VOC and adapt public health interventions. This includes
242 microbiological risk definition using S-dropout as an indicator for the Alpha lineage, and the
243 establishment of N501Y-specific RT-PCR assays(15). Another research initiative opted to use an RT-
244 qPCR screening test, facilitating the analysis of a larger sample size within a shorter timeframe and at
245 a reduced cost(16). They identified variants in samples positive for SARS-CoV-2 by an RT-qPCR
246 mutation screening kit and subsequently confirmed through Next Generation Sequencing (NGS).
247 During the early stages of the COVID-19 pandemic in Argentina, variant surveillance was initiated
248 using WGS. In February 2021, they changed their strategy to partial S gene sequencing due to a
249 significant increase in demand for WGS. However, both sequencing approaches were time-consuming

250 which resulted in delayed identification of variants. They then established an algorithm using an RT-
251 qPCR strategy that targeted the N501Y, E484K, and L452 mutations(17). Similarly, our optimized
252 assay would have been a useful tool for more rapid identification of variants in the country had it been
253 included in our surveillance initiatives as a screening step. Our findings provide use-case evidence of
254 how the limitations of WGS have a big impact on generating an accurate picture of lineage distribution
255 and replacement events. Additionally, it provides evidence of the utility of SNP RT-qPCR assays for
256 variant detection and surveillance in tandem with WGS.

257

258 Despite its remarkable diagnostic performance, our optimized assay does not differentiate between the
259 VOCs that share the N501Y SNP which warrants a confirmatory sequencing step to determine the
260 sample's lineage. Moreover, the assay only targets the N501Y SNP which makes it inapplicable for
261 emerging SARS-CoV-2 VOCs that do not carry the SNP. Additional targets may be included similar to
262 other assays that have already been developed(34–36) to screen for other circulating variants. There is
263 a need to continually update the SNP RT-qPCR assays to accommodate EREIDs that rapidly evolve.
264 We only tested archived samples from NCR and Region IV with the earliest collection date of December
265 2020. While the assay was able to uncover a shift in the N501Y SNP's detection rate, we may not have
266 captured potential earlier cases predating December 2020 from other regions. This limits our
267 comprehension of the introductory events of VOCs in the country.

268 Using rapid tools for detecting VOCs is critical, especially during their early stage of spread. As
269 demonstrated by the detection of an unreported earlier VOC case, PCR-based assays offer the fastest
270 and most practical approach for controlling the spread of new variants which warrants prioritization of
271 detection over depth of information. Although currently limited to N501Y mutations, the optimized
272 SNP RT-qPCR assay can be customized to detect other critical mutations, preparing us to identify
273 emerging viral strains with higher public health significance. Integrating these assays into testing
274 algorithms for outbreak response offers a valuable tool for the immediate implementation of efficient
275 evidenced-based control measures. This proactive approach strengthens our preparedness and response
276 to emerging infectious diseases.

277 **CONCLUSIONS**

278 In testing archived samples using the optimized highly sensitive and specific SNP RT-qPCR assay, we
279 detected an earlier Beta variant case in the country that was previously missed because the sample failed
280 to meet the stringent WGS eligibility criteria. As an alternative to the labor- and resource-intensive
281 WGS method, or as a complementary method for variant detection, the assay offers a cheap and rapid
282 way to screen for probable variants and estimate their prevalence in the community. We demonstrate
283 here that PCR-based SNP variant detection assays can be an effective complementary tool in assembling

284 a more accurate picture of SARS-CoV-2 transmission. This highlights its utility for rapid outbreak
285 response and the conduct of subsequent surveillance for emerging SARS-CoV-2 variants. Moreover,
286 its adaptability is valuable in addressing potential outbreaks caused by novel pathogens. Our study also
287 highlights the importance of developing and maintaining in-house capacity for the development of
288 molecular assays that can promptly be adjusted to suit the evolving testing needs given the volatile
289 nature of emerging and re-emerging infectious diseases. As we navigate the evolving challenges of
290 infectious diseases, the importance of the adaptability and effectiveness of these assays becomes
291 apparent, ensuring we remain at the lead in the continuous fight against emerging pathogens.

292 **ACKNOWLEDGMENT**

293 We sincerely thank all the data contributors, namely the authors and their originating laboratories
294 responsible for obtaining the specimens, as well as the submitting laboratories for generating the genetic
295 sequences and metadata. This research is based on their valuable contributions through the GISAID
296 Initiative. We would also like to acknowledge Aldrin V. Imbag and Fatima Rose S. Guemo for
297 maintaining the HPC cluster used in this study. The preparation of this manuscript benefited from
298 guidance and discussion at Project BUKLOD's Academic Writing Course in June 2023 (funded by the
299 German Alliance for Global Health Research).

300 **SUPPLEMENTAL DATA**

301 Table S1. Limit of detection raw data.

Replicate	N501		501Y	
	3.01 copies/ μ L	0.301 copies/ μ L	3.01 copies/ μ L	0.301 copies/ μ L
1	Detected	Not Detected	Detected	Detected
2	Detected	Not Detected	Detected	Not Detected
3	Detected	Not Detected	Detected	Detected
4	Detected	Not Detected	Detected	Not Detected
5	Detected	Not Detected	Detected	Detected
6	Detected	Detected	Detected	Detected
7	Detected	Not Detected	Detected	Detected
8	Detected	Not Detected	Detected	Detected
9	Detected	Not Detected	Detected	Detected
10	Detected	Not Detected	Detected	Detected
11	Detected	Not Detected	Detected	Not Detected
12	Detected	Detected	Detected	Not Detected
13	Detected	Not Detected	Detected	Detected
14	Detected	Not Detected	Detected	Not Detected
15	Detected	Not Detected	Not Detected	Not Detected
16	Detected	Detected	Detected	Not Detected
17	Detected	Detected	Detected	Not Detected
18	Detected	Not Detected	Detected	Not Detected
19	Detected	Not Detected	Detected	Detected
20	Detected	Not Detected	Detected	Detected
No. of Replicates	20	20	20	20
No. of positives	20	4	19	11
% Detected	100	20	95	55

303 **Data Availability**

304 GISAID Identifier: EPI_SET_230914kr

305 <https://doi.org/10.55876/gis8.230914kr>

306

307 All genome sequences and associated metadata in this dataset are published in GISAID's EpiCoV
308 database. To view the contributors of each individual sequence with details such as accession number,
309 Virus name, Collection date, Originating Lab and Submitting Lab, and the list of Authors, visit
310 [10.55876/gis8.230914kr](https://doi.org/10.55876/gis8.230914kr)

311

312 **Data Snapshot**

313

- 314 ● EPI_SET_230914kr is composed of 57 individual genome sequences.
- 315 ● The collection dates range from 2021-02-08 to 2021-06-28;
- 316 ● Data were collected in 1 countries and territories;
- 317 ● All sequences in this dataset are compared relative to hCoV-19/Wuhan/WIV04/2019 (WIV04),
318 the official reference sequence employed by GISAID (EPI_ISL_402124). Learn more at
319 <https://gisaid.org/WIV04>.

320 **REFERENCES**

- 321 1. WHO. Global genomic surveillance strategy for pathogens with pandemic and epidemic potential, 2022–
322 2032. 2022; Available from: <https://www.who.int/publications-detail-redirect/9789240046979>
- 323 2. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2
324 variants, spike mutations and immune escape. *Nat Rev Microbiol*. 2021 Jul;19(7):409–24.
- 325 3. Rambaut A, Loman N, Pybus O, Barclay W, Barrett J, Carabelli A, et al. Preliminary genomic
326 characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations
327 [Internet]. 2020 Dec. Available from: <https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563>
328
- 329 4. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Detection of a SARS-
330 CoV-2 variant of concern in South Africa. *Nature*. 2021 Apr 15;592(7854):438–43.
- 331 5. Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DDS, Mishra S, et al. Genomics and epidemiology
332 of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. *Science*. 2021 May 21;372(6544):815–21.
- 333 6. Leung K, Shum MH, Leung GM, Lam TT, Wu JT. Early transmissibility assessment of the N501Y mutant
334 strains of SARS-CoV-2 in the United Kingdom, October to November 2020. *Eurosurveillance* [Internet].
335 2021 Jan 7 [cited 2023 Sep 27];26(1). Available from:
336 <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.26.1.2002106>
- 337 7. Tian F, Tong B, Sun L, Shi S, Zheng B, Wang Z, et al. N501Y mutation of spike protein in SARS-CoV-2
338 strengthens its binding to receptor ACE2. *eLife*. 2021 Aug 20;10:e69091.
- 339 8. Williams AH, Zhan CG. Fast Prediction of Binding Affinities of the SARS-CoV-2 Spike Protein Mutant
340 N501Y (UK Variant) with ACE2 and Miniprotein Drug Candidates. *J Phys Chem B*. 2021 May
341 6;125(17):4330–6.
- 342 9. Liu Y, Liu J, Plante KS, Plante JA, Xie X, Zhang X, et al. The N501Y spike substitution enhances SARS-
343 CoV-2 transmission [Internet]. *Microbiology*; 2021 Mar [cited 2023 Nov 30]. Available from:
344 <http://biorxiv.org/lookup/doi/10.1101/2021.03.08.434499>
- 345 10. Sandoval Torrientes M, Castelló Abietar C, Boga Riveiro J, Álvarez-Argüelles ME, Rojo-Alba S, Abreu
346 Salinas F, et al. A novel single nucleotide polymorphism assay for the detection of N501Y SARS-CoV-2
347 variants. *J Virol Methods*. 2021 Aug;294:114143.
- 348 11. ECDC, WHO. Methods for the detection and characterisation of SARS-CoV-2 variants - second update
349 [Internet]. 2022 Aug. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Methods-for-the-detection-char-SARS-CoV-2-variants_2nd%20update_final.pdf
350
- 351 12. Specchiarello E, Matusali G, Carletti F, Gruber CEM, Fabeni L, Minosse C, et al. Detection of SARS-CoV-
352 2 Variants via Different Diagnostics Assays Based on Single-Nucleotide Polymorphism Analysis.
353 *Diagnostics*. 2023 Apr 27;13(9):1573.
- 354 13. Abdulnoor M, Eshaghi A, Perusini SJ, Broukhanski G, Corbeil A, Cronin K, et al. Real-Time RT-PCR
355 Allelic Discrimination Assay for Detection of N501Y Mutation in the Spike Protein of SARS-CoV-2
356 Associated with B.1.1.7 Variant of Concern. Bard JD, editor. *Microbiol Spectr*. 2022 Feb 23;10(1):e00681-
357 21.
- 358 14. Gomes L, Jeewandara C, Jayadas TP, Dissanayake O, Harvie M, Guruge D, et al. Surveillance of SARS-
359 CoV-2 variants of concern by identification of single nucleotide polymorphisms in the spike protein by a
360 multiplex real-time PCR. *J Virol Methods*. 2022 Feb;300:114374.

- 361 15. Goncalves Cabecinhas AR, Roloff T, Stange M, Bertelli C, Huber M, Ramette A, et al. SARS-CoV-2
362 N501Y Introductions and Transmissions in Switzerland from Beginning of October 2020 to February
363 2021—Implementation of Swiss-Wide Diagnostic Screening and Whole Genome Sequencing.
364 *Microorganisms*. 2021 Mar 25;9(4):677.
- 365 16. Muñoz-Valle JF, Venancio-Landeros AA, Sánchez-Sánchez R, Reyes-Díaz K, Galindo-Ornelas B,
366 Hernández-Monjaraz WS, et al. An Upgrade on the Surveillance System of SARS-CoV-2: Deployment of
367 New Methods for Genetic Inspection. *Int J Mol Sci*. 2022 Mar 15;23(6):3143.
- 368 17. Castro GM, Sicilia P, Bolzon ML, Lopez L, Barbás MG, Pisano MB, et al. Tracking SARS-CoV-2 Variants
369 Using a Rapid Typification Strategy: A Key Tool for Early Detection and Spread Investigation of Omicron
370 in Argentina. *Front Med*. 2022 May 17;9:851861.
- 371 18. Miyamoto S, Arashiro T, Ueno A, Kanno T, Saito S, Katano H, et al. Non-Omicron breakthrough infection
372 with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5
373 neutralization. *iScience*. 2023 Feb;26(2):105969.
- 374 19. Université de Genève, Hôpitaux Universitaires de Genève. Protocol for specific RT-PCRs for marker
375 regions of the Spike region indicative of the UK SARS-CoV2 variant B.1.1.7 and the South African variant
376 501Y.V2 [Internet]. 2020 Dec. Available from:
377 [https://www.hug.ch/sites/interhug/files/structures/laboratoire_de_virologie/protocol_amplification_voc_20](https://www.hug.ch/sites/interhug/files/structures/laboratoire_de_virologie/protocol_amplification_voc_20201201_uk_geneva.pdf)
378 [201201_uk_geneva.pdf](https://www.hug.ch/sites/interhug/files/structures/laboratoire_de_virologie/protocol_amplification_voc_20201201_uk_geneva.pdf)
- 379 20. Larsson A. AliView: a fast and lightweight alignment viewer and editor for large datasets. *Bioinformatics*.
380 2014 Nov 15;30(22):3276–8.
- 381 21. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: Molecular Evolutionary Genetics Analysis
382 across Computing Platforms. Battistuzzi FU, editor. *Mol Biol Evol*. 2018 Jun 1;35(6):1547–9.
- 383 22. Stanford Coronavirus Antiviral & Resistance Database (CoVDB) [Internet]. [cited 2023 Oct 9]. Available
384 from: <https://covdb.stanford.edu/sierra/sars2/by-sequences/>
- 385 23. Quick J. nCoV-2019 sequencing protocol v1 [Internet]. 2020 [cited 2024 Jun 18]. Available from:
386 <https://www.protocols.io/view/ncov-2019-sequencing-protocol-bbmuik6w>
- 387 24. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data – from vision to reality.
388 *Eurosurveillance* [Internet]. 2017 Mar 30 [cited 2023 Oct 4];22(13). Available from:
389 <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2017.22.13.30494>
- 390 25. Katoh K. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform.
391 *Nucleic Acids Res*. 2002 Jul 15;30(14):3059–66.
- 392 26. Nguyen LT, Schmidt HA, Von Haeseler A, Minh BQ. IQ-TREE: A Fast and Effective Stochastic
393 Algorithm for Estimating Maximum-Likelihood Phylogenies. *Mol Biol Evol*. 2015 Jan;32(1):268–74.
- 394 27. Sagulenko P, Puller V, Neher RA. TreeTime: Maximum-likelihood phylodynamic analysis. *Virus Evol*
395 [Internet]. 2018 Jan 1 [cited 2023 Nov 30];4(1). Available from:
396 <http://academic.oup.com/ve/article/doi/10.1093/vex042/4794731>
- 397 28. Young M, Crook H, Scott J, Edison P. Covid-19: virology, variants, and vaccines. *BMJ Med*. 2022
398 Mar;1(1):e000040.
- 399 29. DOH. PH Genomic Biosurveillance Detects SARS-CoV-2 UK Variant [Internet]. 2021 Jan. Available
400 from: [https://doh.gov.ph/doh-press-release/PH-GENOMIC-BIOSURVEILLANCE-DETECTS-SARS-](https://doh.gov.ph/doh-press-release/PH-GENOMIC-BIOSURVEILLANCE-DETECTS-SARS-COV-2-UK-VARIANT)
401 [COV-2-UK-VARIANT](https://doh.gov.ph/doh-press-release/PH-GENOMIC-BIOSURVEILLANCE-DETECTS-SARS-COV-2-UK-VARIANT)
- 402 30. PGC. PGC SARS-CoV-2 Bulletin No. 6: First case of the new variant under Lineage B.1.1.7 detected in
403 the Philippines [Internet]. 2021 Jan. Available from: <https://pgc.up.edu.ph/pgc-sars-cov-2-bulletin-no-6/>

- 404 31. Pan American Health Organization. Guidance for SARS-CoV-2 samples selection for genomic
405 characterization and surveillance [Internet]. 2021. Available from:
406 <https://www.paho.org/en/file/82020/download?token=dUPSGHUm>
- 407 32. Sansure Biotech, Inc. Novel Coronavirus (2019-nCoV) Nucleic Acid Diagnostic Kit (PCR-Fluorescence
408 Probing) Instructions for Use V02. 2022.
- 409 33. Ropero G. PH reports 10,019 more COVID-19 cases, total now at 2,632,881. ABS-CBN News. 2021 Oct 7;
- 410 34. Martinez M, Nguyen PV, Su M, Cardozo F, Valenzuela A, Franco L, et al. SARS-CoV-2 Variants in
411 Paraguay: Detection and Surveillance with an Economical and Scalable Molecular Protocol. *Viruses*. 2022
412 Apr 22;14(5):873.
- 413 35. Nörz D, Grunwald M, Tang HT, Olearo F, Günther T, Robitaille A, et al. Rapid Automated Screening for
414 SARS-CoV-2 B.1.617 Lineage Variants (Delta/Kappa) through a Versatile Toolset of qPCR-Based SNP
415 Detection. *Diagnostics*. 2021 Oct 1;11(10):1818.
- 416 36. Wang H, Miller JA, Verghese M, Sibai M, Solis D, Mfuh KO, et al. Multiplex SARS-CoV-2 Genotyping
417 Reverse Transcriptase PCR for Population-Level Variant Screening and Epidemiologic Surveillance.
418 McAdam AJ, editor. *J Clin Microbiol*. 2021 Jul 19;59(8):e00859-21.

419